Condition (MeSH)
Uveomeningoencephalitic Syndrome
ClinicalTrials.gov lists 13 trials for Uveomeningoencephalitic Syndrome or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
13 of the 13 trials are tagged with Uveomeningoencephalitic Syndrome itself; the rest are tagged with a narrower condition beneath it.
When did Uveomeningoencephalitic Syndrome trials start? (8)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2022 | 1 |
| 2021 | 4 |
| 2020 | 1 |
| 2019 | 3 |
| 2015 | 1 |
| 2012 | 1 |
| 2011 | 1 |
| 2006 | 1 |
No forecast is made for this condition: it averages 0.6 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Uveomeningoencephalitic Syndrome trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2/3 | 1 |
| Phase 3 | 1 |
| Not applicable | 4 |
| Observational | 7 |
How many Uveomeningoencephalitic Syndrome trials are recruiting? (4)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Completed | 4 |
| Withdrawn | 1 |
| Unknown status | 7 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Bevacizumab 1 | 2 |
| Adalimumab-US | 1 |
| Intravitreal Injection of Bevacizumab (1.25 mg/0.05ml) | 1 |
| Steroids | 1 |
| Suprachoroidal Triamcinolone acetonide injection for serous retinal detachment in VKH disease | 1 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Uveomeningoencephalitic Syndrome? (29)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Association Between Baseline Macular Morphologic Features on Optical Coherence Tomography and Visual Outcomes in Patients with Vogt-Koyanagi-Harada Disease. | Ocular immunology and inflammation | 2025 | Yes |
| Clinical features and visual outcomes of 111 patients with new-onset acute Vogt-Koyanagi-Harada disease treated with pulse intravenous corticosteroids. | The British journal of ophthalmology | 2019 | Yes |
| Catching the therapeutic window of opportunity in early initial-onset Vogt-Koyanagi-Harada uveitis can cure the disease. | International ophthalmology | 2019 | Yes |
| Longitudinal Study of Visual Function in Vogt-Koyanagi-Harada Disease Using Full-Field Electroretinography. | American journal of ophthalmology | 2018 | Yes |
| Reappraisal of the management of Vogt-Koyanagi-Harada disease: sunset glow fundus is no more a fatality. | International ophthalmology | 2017 | Yes |
Showing 5 of 29 publications.
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Vogt-Koyanagi-Harada disease | Annual incidence | 1-9 / 1 000 000 | United States | US | Unspecified |
| Vogt-Koyanagi-Harada disease | Annual incidence | 1-9 / 1 000 000 | United States | US | Exact |
| Vogt-Koyanagi-Harada disease | Annual incidence | 1-9 / 1 000 000 | United States | US | Exact |
| Vogt-Koyanagi-Harada disease | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
| Vogt-Koyanagi-Harada disease | Point prevalence | Unknown | Worldwide | Not stated | Exact |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Vogt-Koyanagi-Harada disease | 3437 | Exact | Orphadata Science knowledge files, Product 1 |
| Vogt-Koyanagi-Harada disease | 3437 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: lead sponsors, serious adverse events in this condition's trials, and sub-conditions in mesh.